Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 15/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 15/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 15/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1175786 | 0.85 | MEN1 (0.41) | ADORA1GPR119 | |
| SCHEMBL23144566 | 0.82 | GABRG2 (0.43) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL1174623 | 0.80 | NR1H2 (0.50) | ATMGPR119 | |
| SCHEMBL15247956 | 0.80 | GABRG2 (0.48) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL30793790 | 0.78 | ADORA1 (0.43) | ADORA1ATMGPR119 | |
| SCHEMBL22615432 | 0.77 | ADORA1 (0.42) | ADORA1ATMGPR119 | |
| SCHEMBL12866909 | 0.77 | ADORA1 (0.42) | ADORA1ATMGPR119 | |
| SCHEMBL31323684 | 0.77 | ADORA1 (0.42) | ADORA1GABRG2GABRB3GABRA5ATM | |
| SCHEMBL31699998 | 0.77 | MEN1 (0.39) | ADORA1GABRG2GABRB3GABRA5ATM | |
| SCHEMBL30793765 | 0.77 | ADORA1 (0.42) | ADORA1ATMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859538-B2 | Uses of substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859538-B2 | Uses of substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2170350-B1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-7517874-B2 | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain | CARA THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517874-B2 | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain | CARA THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157751-A2 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | ADORA1 378/4885GABRG2 476/4885GABRB3 558/4885 |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CNR2, CNR1, TRPV1 | ADORA1 586/4885GABRG2 521/4885GABRB3 541/4885 |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | ADORA1 378/4885GABRG2 476/4885GABRB3 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.